PPH
VanEck Pharmaceutical ETF
PPH
VanEck Pharmaceutical ETF
-
NAV$116.61
as of August 21, 2026 -
YTD RETURNS14.65%
as of August 21, 2026 -
Total Net Assets$1.07B
as of August 21, 2026 -
Total Expense Ratio0.36%
-
Inception Date12/20/2011
Overview
Why PPH
- Highly Liquid CompaniesTracks the largest most liquid pharmaceutical companies
- Industry LeadersFavors established industry leaders with meaningful scale
- Global ScopeProvides exposure to U.S. and international equities for global industry representation
VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Performance
Average Annual Total Returns* (%)
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | 1.42 | 8.94 | 8.49 | 35.82 | 13.41 | 10.23 | 7.99 | 10.19 |
| PPH (Market Price) | 1.53 | 9.00 | 8.49 | 35.95 | 13.43 | 10.23 | 7.99 | 10.27 |
| MVIS US Listed Pharmaceutical 25 Index | 1.46 | 8.88 | 8.28 | 35.59 | 13.04 | 9.86 | 7.74 | 10.00 |
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | 4.42 | 5.83 | 6.97 | 27.15 | 13.83 | 10.55 | 8.46 | 10.15 |
| PPH (Market Price) | 4.40 | 6.13 | 6.86 | 27.12 | 13.83 | 10.52 | 8.46 | 10.22 |
| MVIS US Listed Pharmaceutical 25 Index | 4.38 | 5.74 | 6.73 | 26.87 | 13.35 | 10.15 | 8.20 | 9.95 |
Holdings
Book a 15-minute call to learn more about the holdings.
Daily Holdings (%) as of 08/20/2026
Download XLS|
Ticker
|
Holding Name |
% of Net Assets
|
Market Value (US$)
|
|---|---|---|---|
|
LLY |
Eli Lilly & Co |
19.98 |
211,045,262 |
|
MRK |
Merck & Co Inc |
10.87 |
114,777,575 |
|
NVS |
Novartis Ag |
10.08 |
106,509,589 |
|
PFE |
Pfizer Inc |
4.95 |
52,300,252 |
|
NVO |
Novo Nordisk A/S |
4.92 |
51,927,156 |
|
BMY |
Bristol-Myers Squibb Co |
4.83 |
51,058,089 |
|
ABBV |
Abbvie Inc |
4.53 |
47,861,477 |
|
JNJ |
Johnson & Johnson |
4.36 |
46,095,390 |
|
MCK |
Mckesson Corp |
4.36 |
46,009,631 |
|
GSK |
Gsk Plc |
4.17 |
44,030,436 |
|
SNY |
Sanofi Sa/France |
4.03 |
42,608,371 |
|
AZN |
Astrazeneca Plc |
3.58 |
37,795,032 |
|
COR |
Cencora Inc |
3.55 |
37,524,580 |
|
TEVA |
Teva Pharmaceutical Industries Ltd |
3.16 |
33,405,848 |
|
HLN |
Haleon Plc |
3.11 |
32,875,529 |
|
TAK |
Takeda Pharmaceutical Co Ltd |
3.09 |
32,657,642 |
|
ZTS |
Zoetis Inc |
2.09 |
22,029,698 |
|
JAZZ |
Jazz Pharmaceuticals Plc |
1.06 |
11,214,132 |
|
VTRS |
Viatris Inc |
1.05 |
11,093,360 |
|
CORT |
Corcept Therapeutics Inc |
0.67 |
7,054,189 |
|
AXSM |
Axsome Therapeutics Inc |
0.62 |
6,560,434 |
|
ELAN |
Elanco Animal Health Inc |
0.32 |
3,399,896 |
|
OGN |
Organon & Co |
0.22 |
2,337,820 |
|
BHC |
Bausch Health Cos Inc |
0.13 |
1,359,576 |
|
PRGO |
Perrigo Co Plc |
0.08 |
796,655 |
|
-USD CASH- |
-- |
0.00 |
540 |
|
-- |
Other/Cash |
0.19 |
2,023,339 |
Portfolio
- Market Capitalization (%)
- Currency Exposure (%)
- Sector Weightings (%)
- Country Weightings (%)
Sector Weightings (%) as at 07/31/2026
-
Sector
% of Net Assets -
Health Care
99.95 -
Other/Cash
0.05
Country Weightings (%) as at 07/31/2026
-
Country
% of Net Assets -
United States
62.64 -
United Kingdom
11.41 -
Switzerland
10.50 -
Denmark
5.23 -
France
4.01 -
Israel
3.13 -
Japan
3.04 -
Other/Cash
0.05
Fees
Distributions
as of 08/21/2026
Quarterly
1.81%
2.14%
1.86%
Team
Resources
Regulatory Information
-
Name
Frequency - Annually
- Annually
-
Statement of Additional Information (SAI)
Annually - Annually
- Annually
Fund Documents
-
Name
Frequency -
PPH Fund Profile: A Perfect Prescription for Growth Portfolios
- Daily
-
VanEck Tax Information & Distributions
Annually -
NAV & Premium/Discount History
Daily - Annually
Thought Leadership
-
Name
Frequency